source
- Cardiac biotech Braveheart raises $382.5M in IPO, launches on Nasdaq as BRVEBraveheart Bio, a cardiac drug developer, priced its initial public offering on Wednesday and secured $382.5 million in proceeds. The company sold about 21.2 million shares at $18 each, exceeding t…
- Experts call for independent 9/11‑style commission to review U.S. Covid responseIn an opinion piece, IDSA President Ronald Nahass argues that the United States should create a nonpartisan, 9/11 Commission‑style body to examine the Covid‑19 response. He says such an inquiry wou…